The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Titel:
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
Auteur:
Ackler, Scott Mitten, Michael J. Foster, Kelly Oleksijew, Anatol Refici, Marion Tahir, Stephen K. Xiao, Yu Tse, Christin Frost, David J. Fesik, Stephen W. Rosenberg, Saul H. Elmore, Steven W. Shoemaker, Alexander R.